TIMOLOL MALEATE

Timolol Maleate Adverse Events Reported to the FDA Over Time

How are Timolol Maleate adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Timolol Maleate, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Timolol Maleate is flagged as the suspect drug causing the adverse event.

Most Common Timolol Maleate Adverse Events Reported to the FDA

What are the most common Timolol Maleate adverse events reported to the FDA?

Intraocular Pressure Increased	98 (2.49%)
Eye Irritation	83 (2.1%)
Eye Pain	61 (1.55%)
Drug Ineffective	60 (1.52%)
Bradycardia	56 (1.42%)
Ocular Hyperaemia	54 (1.37%)
Visual Acuity Reduced	45 (1.14%)
Blindness	44 (1.12%)
Dizziness	44 (1.12%)
Vision Blurred	42 (1.07%)
Corneal Deposits	39 (.99%)
	Show More
Drug Interaction	36 (.91%)
Dyspnoea	35 (.89%)
Visual Impairment	34 (.86%)
Fatigue	33 (.84%)
Product Substitution Issue	33 (.84%)
Eye Pruritus	29 (.74%)
Erythema	27 (.68%)
Heart Rate Decreased	27 (.68%)
Hypotension	27 (.68%)
Anxiety	26 (.66%)
Eye Disorder	25 (.63%)
Headache	25 (.63%)
Hypersensitivity	24 (.61%)
Malaise	24 (.61%)
Cataract	23 (.58%)
Fall	23 (.58%)
Glaucoma	21 (.53%)
Skin Exfoliation	21 (.53%)
Chest Pain	20 (.51%)
Ectropion	20 (.51%)
Eyelid Oedema	20 (.51%)
Cough	19 (.48%)
Eye Swelling	19 (.48%)
Loss Of Consciousness	19 (.48%)
Arrhythmia	18 (.46%)
Asthma	18 (.46%)
Choroidal Detachment	18 (.46%)
Drug Hypersensitivity	18 (.46%)
Metabolic Acidosis	18 (.46%)
Nausea	18 (.46%)
Atrial Fibrillation	17 (.43%)
Conjunctival Oedema	17 (.43%)
Eye Inflammation	17 (.43%)
Eye Movement Disorder	17 (.43%)
Lethargy	17 (.43%)
Periorbital Oedema	17 (.43%)
Pruritus	17 (.43%)
Blood Pressure Increased	16 (.41%)
Dermatitis	16 (.41%)
Dry Eye	16 (.41%)
Pain	16 (.41%)
Syncope	16 (.41%)
Accidental Exposure	15 (.38%)
Atrioventricular Block Complete	15 (.38%)
Iris Adhesions	15 (.38%)
Miosis	15 (.38%)
Peripheral Coldness	15 (.38%)
Respiratory Rate Decreased	15 (.38%)
Atrioventricular Block	14 (.36%)
Blood Pressure Decreased	14 (.36%)
Corneal Epithelium Defect	14 (.36%)
Deafness	14 (.36%)
Hypertension	14 (.36%)
Keratopathy	14 (.36%)
Palpitations	14 (.36%)
Tinnitus	14 (.36%)
Abdominal Pain	13 (.33%)
Alopecia	13 (.33%)
Chest Discomfort	13 (.33%)
Conjunctival Hyperaemia	13 (.33%)
Corneal Disorder	13 (.33%)
Depressed Level Of Consciousness	13 (.33%)
Eye Haemorrhage	13 (.33%)
Feeling Abnormal	13 (.33%)
Hypotonia	13 (.33%)
Lacrimation Increased	13 (.33%)
Ulcerative Keratitis	13 (.33%)
Visual Field Defect	13 (.33%)
Asthenia	12 (.3%)
Blindness Transient	12 (.3%)
Condition Aggravated	12 (.3%)
Vitreous Haemorrhage	12 (.3%)
Blepharoplasty	11 (.28%)
Drug Effect Decreased	11 (.28%)
Eye Infection	11 (.28%)
Keratitis	11 (.28%)
Keratitis Herpetic	11 (.28%)
Medication Error	11 (.28%)
Wrong Drug Administered	11 (.28%)
Cardiac Arrest	10 (.25%)
Cardiotoxicity	10 (.25%)
Confusional State	10 (.25%)
Developmental Glaucoma	10 (.25%)
Diarrhoea	10 (.25%)
Hypotony Of Eye	10 (.25%)
Intraocular Pressure Test Abnormal	10 (.25%)
Nervous System Disorder	10 (.25%)
Paralysis	10 (.25%)
Pneumonia	10 (.25%)
Pulse Abnormal	10 (.25%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Timolol Maleate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Timolol Maleate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Timolol Maleate

What are the most common Timolol Maleate adverse events reported to the FDA?

Ocular Infections, Irritations And ...	332 (8.42%)
Vision	211 (5.35%)
Cardiac Arrhythmias	185 (4.69%)
Anterior Eye Structural Change, Dep...	181 (4.59%)
Eye	179 (4.54%)
Neurological	178 (4.51%)
Epidermal And Dermal Conditions	144 (3.65%)
Therapeutic And Nontherapeutic Effe...	126 (3.2%)
Neurological, Special Senses And Ps...	122 (3.09%)
Respiratory	109 (2.76%)
Cardiac And Vascular Investigations	102 (2.59%)
	Show More
Medication Errors	86 (2.18%)
Injuries	62 (1.57%)
Product Quality Issues	58 (1.47%)
Gastrointestinal Signs	54 (1.37%)
Ocular Structural Change, Deposit A...	49 (1.24%)
Ocular Neuromuscular	47 (1.19%)
Allergic Conditions	46 (1.17%)
Decreased And Nonspecific Blood Pre...	43 (1.09%)
Eye Therapeutic Procedures	42 (1.07%)
Infections - Pathogen Unspecified	41 (1.04%)
Cardiac Disorder Signs	36 (.91%)
Glaucoma And Ocular Hypertension	35 (.89%)
Anxiety Disorders	34 (.86%)
Physical Examination Topics	34 (.86%)
Bronchial Disorders	33 (.84%)
Skin Appendage Conditions	33 (.84%)
Headaches	27 (.68%)
Procedural And Device Related Injur...	26 (.66%)
Retina, Choroid And Vitreous Hemorr...	26 (.66%)
Electrolyte And Fluid Balance Condi...	25 (.63%)
Ocular Hemorrhages And Vascular	25 (.63%)
Angiedema And Urticaria	22 (.56%)
Water, Electrolyte And Mineral	22 (.56%)
Arteriosclerosis, Stenosis, Vascula...	21 (.53%)
Coronary Artery	21 (.53%)
Hearing	21 (.53%)
Neuromuscular	21 (.53%)
Ocular Sensory Symptoms	21 (.53%)
Renal Disorders	21 (.53%)
Viral Infectious	21 (.53%)
Acid-base	20 (.51%)
Muscle	20 (.51%)
Inner Ear And Viiith Cranial Nerve	19 (.48%)
Lifestyle Issues	19 (.48%)
Movement Disorders	19 (.48%)
Gastrointestinal Motility And Defec...	18 (.46%)
Bone And Joint Injuries	17 (.43%)
Vascular Hypertensive	16 (.41%)
Deliria	15 (.38%)
Hematology Investigations	15 (.38%)
Neurological Disorders Of The Eye	15 (.38%)
Renal And Urinary Tract Investigati...	15 (.38%)
Administration Site Reactions	14 (.36%)
Central Nervous System Vascular	14 (.36%)
Heart Failures	14 (.36%)
Hepatobiliary	14 (.36%)
Mental Impairment	14 (.36%)
Nephropathies	14 (.36%)
Sleep Disorders	14 (.36%)
Platelet	13 (.33%)
Thyroid Gland	13 (.33%)
Fatal Outcomes	12 (.3%)
Metastases	12 (.3%)
Therapeutic Procedures And Supporti...	12 (.3%)
Urinary Tract Signs	12 (.3%)
Chemical Injury And Poisoning	11 (.28%)
Joint	11 (.28%)
Oral Soft Tissue Conditions	11 (.28%)
Upper Respiratory Tract Disorders	11 (.28%)
Vascular	11 (.28%)
Cranial Nerve Disorders	10 (.25%)
Embolism And Thrombosis	10 (.25%)
Eye Disorders Congenital	10 (.25%)
Musculoskeletal And Connective Tiss...	10 (.25%)
Body Temperature Conditions	9 (.23%)
Depressed Mood Disorders	9 (.23%)
Disturbances In Thinking	9 (.23%)
Metabolic, Nutritional And Blood Ga...	9 (.23%)
Musculoskeletal And Connective Tiss...	9 (.23%)
Skin Vascular Abnormalities	9 (.23%)
Appetite And General Nutritional	8 (.2%)
Glucose Metabolism Disorders	8 (.2%)
Immunology And Allergy	8 (.2%)
Lipid Analyses	8 (.2%)
Lower Respiratory Tract Disorders	8 (.2%)
Peripheral Neuropathies	8 (.2%)
Bacterial Infectious	7 (.18%)
Gastrointestinal Hemorrhages	7 (.18%)
Miscellaneous And Site Unspecified ...	7 (.18%)
Pleural	7 (.18%)
Pulmonary Vascular	7 (.18%)
Respiratory And Mediastinal Neoplas...	7 (.18%)
White Blood Cell	7 (.18%)
Mood Disorders	6 (.15%)
Cognitive And Attention Disorders	5 (.13%)
Cutaneous Neoplasms Benign	5 (.13%)
Gastrointestinal Neoplasms Malignan...	5 (.13%)
Hypothalamus And Pituitary Gland	5 (.13%)
Injuries By Physical Agents	5 (.13%)
Pigmentation	5 (.13%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Timolol Maleate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Timolol Maleate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.